EGFR and non-small cell lung carcinoma: Acclaim 1 is a randomized study that aims to determine the safety and efficacy of quaratusugene ezeplasmid added to Osimertinib in NSCLC patients with mutated EGFR and who have progressed with Osimertinib [172,173].